High dose rDNA human alpha 2 interferon therapy in patients with advanced colorectal adenocarcinoma: a phase II study.

Abstract

Eighteen patients with advanced and inoperable colorectal adenocarcinomas were treated with high doses of alpha 2 Interferon (Schering-Plough Corporation). The patients were randomized to receive either subcutaneous injections of 20 X 10(6) I.U./m2 three times weekly for 3 months, or pulsed treatments of 50 X 10(6) I.U./m2 daily, given intravenously, for 5 consecutive days every 4 weeks. No objective tumour regression was seen in any patient. The side effects were considerable.

• Authors: G Lundell, H Blomgren, B Cedermark, C Silfverswärd, T Theve, U Ohman
• Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (Radiother Oncol) Vol. 1 Issue 4 Pg. 325-32 (Mar 1984) ISSN: 0167-8140 [Print] Ireland
• PMID: 6505269 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Interferon Type I

Topics

• Adenocarcinoma (therapy)
• Adult
• Colonic Neoplasms (therapy)
• Drug Evaluation
• Female
• Humans
• Interferon Type I (adverse effects, therapeutic use)
• Leukocyte Count
• Male
• Middle Aged
• Patient Compliance
• Platelet Count
• Rectal Neoplasms (therapy)